Olanzapine, aripiprazole, amisulpride and quetiapine – the reasons to use it in the schizophrenia treatment Review article
Article Sidebar
Published:
Mar 31, 2019
Keywords:
schizophrenia, aripiprazole, amisulpride, olanzapine, quetiapine
Main Article Content
Abstract
The main objective of this article is to provide basic information about four commonly used antipsychotic drugs: aripiprazole, amisulpride, olanzapine and quetiapine. Main differences in their efficacy against positive, negative, cognitive and depressive symptoms of schizophrenia are summarized. Using a framework that balances clinical profile of the drug and the tolerability and safety concerns allow to make more individualised treatment choices for patients suffering from schizophrenia.
Article Details
How to Cite
Szafrański, T. (2019). Olanzapine, aripiprazole, amisulpride and quetiapine – the reasons to use it in the schizophrenia treatment. Medycyna Faktow (J EBM), 12(1(42), 75-79. https://doi.org/10.24292/01.MF.0119.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Azekawa T., Ohashi S. Itami A.: Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder. Neuropsychiatr. Dis. Treat. 2011; 7: 691-695.
2. Citrome L.: Interpreting and Applying the CATIE Results. Psychiatry (Edgmont) 2007; 4(10): 23-29.
3. Correll C.U.: From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010; 25(supl. 2): S12-S21.
4. Galling B., Roldan A., Rietschel L. et al.: Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin. Drug Saf. 2016; 15(5): 591-612.
5. Hendrick V., Dasher R., Gitlin M., Parsi M.: Minimizing weight gain for patients taking antipsychotic medications: The potential role for early use of metformin. Ann. Clin. Psychiatry 2017; 29(2): 120-124.
6. Kahn R.S., Fleischhacker W.W., Boter H. et al.: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371(9618): 1085-1097.
7. Kahn R.S., Winter van Rossum I., Leucht S. et al.: Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 2018; 5(10): 797-807.
8. Khanna P., Komossa K., Rummel-Kluge C. et al.: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2013; 2: CD006569.
9. Komossa K., Rummel-Kluge C., Hunger H. et al.: Amisulpride versus Other Atypical Antipsychotics for Schizophrenia. Cochrane Database Syst. Rev. 2010; 1: CD006624.
10. Krause M., Zhu Y., Huhn M. et al.: Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2018; 268(7): 625-639. DOI: 10.1007/s00406-018-0869-3.
11. Leucht S., Arbter D., Engel R.R. et al.: How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009; 14(4): 429-447.
12. Leucht S., Cipriani A., Spineli L. et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382(9896): 951-962.
13. Leucht S., Tardy M., Komossa K. et al.: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379(9831): 2063-2071.
14. Mortimer A.M.: Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr. Dis. Treat. 2009; 5: 267-277.
15. Muneer A.: Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. Clin. Psychopharmacol. Neurosci. 2015; 13(1): 25-35.
16. van Rooijen G., Vermeulen J.M., Ruhé H.G., de Haan L.: Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectr. 2017: 1-10.
17. Samara M.T., Dold M., Gianatsi M. et al.: Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry 2016; 73(3): 199-210
18. Solmi M., Murru A., Pacchiarotti I. et al.: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther. Clin. Risk Manag. 2017; 13: 757-777.
19. Temmingh H., Stein D.J.: Anxiety in Patients with Schizophrenia: Epidemiology and Management. CNS Drugs 2015; 29(10): 819-832.
20. Topolov M.K., Getova D.P.: Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole. Folia Medica 2016; 58(1): 12-18.
21. Vancampfort D., Stubbs B., Mitchell A.J. et al.: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015; 14(3): 339-347.
22. Zhu Y., Krause M., Huhn M. et al.: Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 2017; 4(9): 694-705.
2. Citrome L.: Interpreting and Applying the CATIE Results. Psychiatry (Edgmont) 2007; 4(10): 23-29.
3. Correll C.U.: From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010; 25(supl. 2): S12-S21.
4. Galling B., Roldan A., Rietschel L. et al.: Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin. Drug Saf. 2016; 15(5): 591-612.
5. Hendrick V., Dasher R., Gitlin M., Parsi M.: Minimizing weight gain for patients taking antipsychotic medications: The potential role for early use of metformin. Ann. Clin. Psychiatry 2017; 29(2): 120-124.
6. Kahn R.S., Fleischhacker W.W., Boter H. et al.: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371(9618): 1085-1097.
7. Kahn R.S., Winter van Rossum I., Leucht S. et al.: Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 2018; 5(10): 797-807.
8. Khanna P., Komossa K., Rummel-Kluge C. et al.: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2013; 2: CD006569.
9. Komossa K., Rummel-Kluge C., Hunger H. et al.: Amisulpride versus Other Atypical Antipsychotics for Schizophrenia. Cochrane Database Syst. Rev. 2010; 1: CD006624.
10. Krause M., Zhu Y., Huhn M. et al.: Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2018; 268(7): 625-639. DOI: 10.1007/s00406-018-0869-3.
11. Leucht S., Arbter D., Engel R.R. et al.: How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009; 14(4): 429-447.
12. Leucht S., Cipriani A., Spineli L. et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382(9896): 951-962.
13. Leucht S., Tardy M., Komossa K. et al.: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379(9831): 2063-2071.
14. Mortimer A.M.: Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr. Dis. Treat. 2009; 5: 267-277.
15. Muneer A.: Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. Clin. Psychopharmacol. Neurosci. 2015; 13(1): 25-35.
16. van Rooijen G., Vermeulen J.M., Ruhé H.G., de Haan L.: Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectr. 2017: 1-10.
17. Samara M.T., Dold M., Gianatsi M. et al.: Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry 2016; 73(3): 199-210
18. Solmi M., Murru A., Pacchiarotti I. et al.: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther. Clin. Risk Manag. 2017; 13: 757-777.
19. Temmingh H., Stein D.J.: Anxiety in Patients with Schizophrenia: Epidemiology and Management. CNS Drugs 2015; 29(10): 819-832.
20. Topolov M.K., Getova D.P.: Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole. Folia Medica 2016; 58(1): 12-18.
21. Vancampfort D., Stubbs B., Mitchell A.J. et al.: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015; 14(3): 339-347.
22. Zhu Y., Krause M., Huhn M. et al.: Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 2017; 4(9): 694-705.